SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFlowtech Fluid. Regulatory News (FLO)

Share Price Information for Flowtech Fluid. (FLO)

Share Price is delayed by 15 minutes
Get Live Data
54.60    -1.40 (-2.50%)
Bid:
52.60
Ask:
56.60
Spread: 4.00 (7.605%)
Market Cap: £45.60m
FLO Live PriceLast checked at - London Stock Exchange

Intraday Flowtech Fluid. Share Chart

Statement

19 May 2008 13:30

RNS Number : 7780U
Flomerics Group PLC
19 May 2008
 



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATESAUSTRALIACANADA OR JAPAN

FOR IMMEDIATE RELEASE

19th May 2008

FLOMERICS GROUP PLC

Statement re: Posting of Offer Document following Unsolicited Offer

 

 

The Board of Directors of Flomerics Group PLC ("Flomerics" or the "Company") notes the statement by Mentor Graphics, Inc. ("Mentor") that it has posted an offer document to Flomerics shareholders in respect of its unsolicited offer for all the outstanding shares and stock options in Flomerics at a price of 104 pence per share payable in cash (the "Offer"). 

 

The Board of Directors of Flomerics continues to believe the Offer materially undervalues the Company and is actively engaged in assessing other alternatives available to the Company, including potential interest expressed by a number of other parties, which are the subject of ongoing discussions. Shareholders are therefore strongly urged to ignore any documents or announcements that may be made or issued by Mentor or its advisers and not to sell their valuable Flomerics shares.

David Mann, Chairman of Flomerics commented: "We have previously stated that the Offer, which is unsolicited, has been considered by the Board of Flomerics, in conjunction with its independent adviser, and we have unanimously concluded that it does not reflect the true value of Flomerics shares. As such, the Offer does not carry the recommendation of the Flomerics Board of Directors as we do not believe it is in the best interests of Flomerics shareholders." 

The Board of Directors intends to write to its shareholders in due course to explain its current position with regard to the Mentor Offer.

Any discussions with other interested parties continue to be at an early stage and there can be no certainty that an alternative offer will be forthcoming. However, shareholders are strongly recommended to take no action at this stage. A further announcement will be made in due course.

 

Enquiries: 

 

Flomerics Group PLC

Gary Carter

Keith Butcher

Tel: 020 8487 3000

Jefferies International Ltd (Financial adviser to Flomerics)

Andres Pieczanski

Sarah McNicholas

Tel: 020 7029 8000

Oriel Securities Limited (Nominated Adviser and Corporate Broker to Flomerics)

Andrew Edwards

Michael Shaw

Tel: 020 7710 7600

Citigate Dewe Rogerson

Ginny Pulbrook

Seb Hoyle

Tel: 020 7638 9571

 

Jefferies International Limited ("Jefferies International"), which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting for Flomerics and no-one else in connection with the matters referred to herein and will not be responsible to anyone other than Flomerics for providing the protections afforded to clients of Jefferies International or for giving advice in relation to such matters.

Oriel Securities Limited ("Oriel Securities"), which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting for Flomerics and no-one else in connection with the matters referred to herein and will not be responsible to anyone other than Flomerics for providing the protections afforded to clients of Oriel Securities or for giving advice in relation to such matters.

 

 Dealing Disclosure Requirements 

Under the provisions of Rule 8.3 of the Takeover Code (the "Code"), if any person is, or becomes, "interested" (directly or indirectly) in 1% or more of any class of "relevant securities" of Flomerics, all "dealings" in any "relevant securities" of that company (including by means of an option in respect of, or a derivative referenced to, any such "relevant securities") must be publicly disclosed by no later than 3.30 pm (London time) on the London business day following the date of the relevant transaction. This requirement will continue until the date on which the offer becomes, or is declared, unconditional as to acceptances, lapses or is otherwise withdrawn or on which the "offer period" otherwise ends. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire an "interest" in "relevant securities" of Nestor, they will be deemed to be a single person for the purpose of Rule 8.3. 

 

Under the provisions of Rule 8.1 of the Code, all "dealings" in "relevant securities" of Flomerics by a potential offeror or by Flomerics, or by any of their respective "associates", must be disclosed by no later than 12.00 noon (London time) on the London business day following the date of the relevant transaction. 

 

A disclosure table, giving details of the companies in whose "relevant securities" "dealings" should be disclosed, and the number of such securities in issue, can be found on the Takeover Panel's website at www.thetakeoverpanel.org.uk. 

"Interests in securities" arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an "interest" by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities. 

 

Terms in quotation marks are defined in the Code, which can also be found on the Takeover Panel's website. If you are in any doubt as to whether or not you are required to disclose a "dealing" under Rule 8, you should consult the Panel.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
OUPGUUAPAUPRGPB
Date   Source Headline
16th Apr 202012:48 pmRNSIssue of Equity and Total Voting Rights
2nd Apr 20207:00 amRNSBusiness Update - COVID-19;Notice of Final results
27th Mar 20202:46 pmRNSDirectorate Changes
6th Mar 202012:15 pmRNSHolding(s) in Company
17th Feb 20207:00 amRNSDirector/PDMR Shareholding
14th Feb 20203:12 pmRNSHolding(s) in Company
13th Feb 20203:58 pmRNSHolding(s) in Company
13th Feb 20207:00 amRNS2019 Trading update & restructuring activities
7th Feb 20204:44 pmRNSHolding(s) in Company
6th Feb 20206:07 pmRNSHolding(s) in Company
20th Jan 20204:13 pmRNSHolding(s) in Company
15th Jan 20204:38 pmRNSHolding(s) in Company
14th Jan 20207:00 amRNSTrading Update - for the year to 31 December 2019
17th Dec 20195:43 pmRNSHolding(s) in Company
5th Dec 20194:41 pmRNSSecond Price Monitoring Extn
5th Dec 20194:35 pmRNSPrice Monitoring Extension
2nd Dec 20194:40 pmRNSSecond Price Monitoring Extn
2nd Dec 20194:35 pmRNSPrice Monitoring Extension
27th Nov 20191:51 pmRNSDirector/PDMR Shareholding
25th Nov 20194:40 pmRNSSecond Price Monitoring Extn
25th Nov 20194:35 pmRNSPrice Monitoring Extension
22nd Nov 20194:40 pmRNSSecond Price Monitoring Extn
22nd Nov 20194:35 pmRNSPrice Monitoring Extension
30th Oct 20199:30 amRNSDirector Share Option Award
28th Oct 20197:00 amRNSDirector/PDMR Shareholding
22nd Oct 20197:00 amRNSTrading update -nine month period to 30 Sept 2019
30th Sep 20194:10 pmRNSCorrection: Director/PDMR Shareholding
30th Sep 201911:32 amRNSDirector/PDMR Shareholding
24th Sep 20197:00 amRNSHalf-Year Report - six months ended 30 June 2019
15th Aug 20191:56 pmRNSDirector/PDMR Shareholding
14th Aug 201912:08 pmRNSSecond Price Monitoring Extn
14th Aug 201912:02 pmRNSPrice Monitoring Extension
30th Jul 20197:00 amRNSIssue of Equity and Total Voting Rights (TVR)
18th Jul 201911:29 amRNSDirector/PDMR Shareholding
16th Jul 201912:07 pmRNSSecond Price Monitoring Extn
16th Jul 201912:02 pmRNSPrice Monitoring Extension
12th Jul 20197:00 amRNSGroup Trading Update & Notice of Half-Year results
13th Jun 201911:25 amRNSIssue of Equity and Total Voting Rights
5th Jun 201910:56 amRNSResults of Voting AGM - 5 June 2019 and TVR
5th Jun 20198:46 amRNS2019 Annual General Meeting Statement
16th May 20197:00 amRNSDeferred Consideration and Total Voting Rights
8th May 20191:35 pmRNSAudited Results - Notice of Annual General Meeting
7th May 201911:34 amRNSHolding(s) in Company
17th Apr 20195:21 pmRNSHolding(s) in Company
16th Apr 20197:00 amRNSPreliminary results - year ended 31 December 2018
16th Apr 20197:00 amRNSQ1 2019 Trading Update
8th Apr 20195:04 pmRNSHolding(s) in Company
26th Mar 20197:00 amRNSHolding(s) in Company
18th Mar 201911:29 amRNSDirector/PDMR Shareholding
19th Feb 20196:30 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.